Anthera Pharmaceuticals (ANTH) Shares Up 7.3%
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) shot up 7.3% during mid-day trading on Friday . The stock traded as high as $2.43 and last traded at $2.34. 1,640,503 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 1,985,417 shares. The stock had previously closed at $2.18.
Several brokerages have issued reports on ANTH. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Roth Capital began coverage on Anthera Pharmaceuticals in a report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 price target for the company. Finally, ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Anthera Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $4.38.
Institutional investors have recently made changes to their positions in the business. Wedbush Securities Inc. boosted its position in shares of Anthera Pharmaceuticals by 75.8% during the third quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 31,800 shares during the period. BVF Inc. IL boosted its position in shares of Anthera Pharmaceuticals by 20.9% during the fourth quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after buying an additional 209,896 shares during the period. 683 Capital Management LLC acquired a new position in shares of Anthera Pharmaceuticals during the fourth quarter worth about $399,000. Finally, Armistice Capital LLC acquired a new position in shares of Anthera Pharmaceuticals during the fourth quarter worth about $1,269,000. Institutional investors own 16.44% of the company’s stock.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.